ArticleCell death & disease2026
STK38-mediated feedback loop regulation of the hedgehog pathway governing tumor heterogeneity in renal papillary carcinoma.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Papillary renal cell carcinoma (pRCC) is characterized by marked intratumoral heterogeneity, which contributes to therapeutic resistance and disease progression. In this study, we identify STK38 as a key regulator of tumor heterogeneity in pRCC, functioning through non-canonical activation of the Hedgehog (Hh) signaling pathway. STK38 interacts with both KIF7 and GSK3β to promote Hh signaling by facilitating KIF7 ciliary localization and reprogramming GSK3β substrate selectivity, leading to GLI1 stabilization and β-catenin suppression. Moreover, GLI1 directly enhances STK38 transcription, establishing a positive feedback loop that reinforces pathway activation. Notably, depletion of STK38 sensitizes tumor cells to a NETosis-like chromatin release process (tNET release), a form of stress-induced nuclear expulsion associated with immune evasion and metastatic potential. Given the potential pro-metastatic consequences of STK38 inhibition, we instead targeted its downstream effector GLI1 using Glabrescione B, which potently suppressed tumor growth and induced apoptosis in both xenograft and patient-derived organoid models, particularly in STK38-high tumors. These findings position STK38 as a critical modulator of pRCC heterogeneity and support GLI1 inhibition as a promising strategy to disrupt oncogenic signaling while minimizing adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.